Daniel Malarek

CEO

Aaron Dungca Needham

Senior Analyst Business Operations and Customer Experience

2 past transactions

Lexent Bio

Acquisition in 2020
LEXENT BIO, INC. develops liquid biopsy technology for the treatment of cancer. It provides clinically actionable information about cancer diagnosis and treatment, and lets clinicians monitor response to the therapy. The company was incorporated in 2014 and is based in San Francisco, California. As of June 12, 2020, LEXENT BIO, INC. operates as a subsidiary of Foundation Medicine, Inc.

COTA Healthcare

Series B in 2016
COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.